Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Neoadjuvant kemoradioterapi med eller uden samtidig azeliragon hos patienter med nyligt diagnosticeret glioblastoma

11. november 2026 opdateret af: Washington University School of Medicine

En tidlig mulighedsvindue tidlig fase I randomiseret undersøgelse af neoadjuvant kemoradioterapi med eller uden samtidig azeliragon hos patienter med nyligt diagnosticeret glioblastoma

Preclinical data have demonstrated the combination of azeliragon, a RAGE inhibitor, with radiation therapy (RT) can effectively reduce immune-suppressive myeloid cells and restore T-cell activation to improve tumor control in murine glioma models. Ongoing clinical studies of azeliragon with RT alone and RT plus temozolomide (TMZ) to treat patients with newly diagnosed glioblastoma (GBM) have demonstrated safety and tolerability. The purpose of this window-of-opportunity study is to validate that the combination of azeliragon with RT and TMZ would modulate immune-suppressive myeloid and T cells in the tumor microenvironment in patients with GBM.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

12

Fase

  • Tidlig fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University School of Medicine

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically proven diagnosis of IDH-wildtype GBM (WHO grade 4) according to the 2021 WHO classification (including subtypes such as gliosarcoma).

  • Radiographic evidence of residual tumor after initial surgery or biopsy.

  • Patient is amenable for future surgery (either surgical resection or laser interstitial thermal therapy (LITT)) to sample the residual tumor after completion of chemoradiotherapy.

  • At least 18 years of age.

  • Eligible for and planning to receive standard fractionated RT of 60 Gy with concurrent TMZ.

  • Recovered from the effects of surgery, postoperative infection, and other complications sufficiently for initiation of chemoradiotherapy, in the opinion of the treating physician.

  • Karnofsky performance status ≥ 60.

  • Adequate organ and bone marrow function as defined below:

    • Absolute neutrophil count (ANC) ≥ 1.5 K/cumm;
    • Platelets ≥ 100 K/cumm;
    • Hemoglobin > 9.0 g/dL (Note: the use of transfusion or other intervention to achieve Hgb >9.0 g/dL is acceptable);
    • Total bilirubin ≤ 1.5 ULN
    • AST (SGOT) and ALT (SGPT) ≤ 3 x ULN
    • Creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 mL/min
    • If there is history of human immunodeficiency virus (HIV) infection, patients must be on effective antiretroviral therapy, and HIV viral load must be undetectable within 6 months of study enrollment.
    • If there is history of chronic hepatitis B virus (HBV) infection, patients must have either been treated or are on suppressive therapy (as indicated), and HBV viral load must be undetectable.
    • If there is history of hepatitis C virus (HCV) infection, patients must have been treated, and HCV viral load must be undetectable.
  • Females of childbearing potential (defined as a female who is non-menopausal or surgically sterilized) and sexually active heterosexual males must be willing to use an acceptable method of birth control (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) during the trial and for 6 months after the last administration of azeliragon. Should a female trial participant or female partner of a male trial participants become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

  • Able to understand and willingness to sign an IRB-approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

  • Prior cranial RT or RT to the head and neck where potential field overlap may exist.
  • Leptomeningeal or metastatic involvement.
  • Known IDH mutation. IDH status could be determined by either immunohistochemistry or sequencing as evaluated per routine clinical care.
  • Patients receiving CYP 2C8 inhibitors within 2 weeks or 5 half-lives prior to study entry.
  • Patients with a gastrointestinal condition that could interfere with swallowing or absorption.
  • Patients with concurrent participation in another interventional clinical trial or use of another investigational agent within 30 days prior to study entry. Patients who are participating in non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.
  • Medical contraindication to MRI (e.g., unsafe foreign metallic implants, incompatible pacemaker, inability to lie still for long periods, severe to end-stage kidney disease or on hemodialysis).
  • Pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of the first dose of RT (Arm 1) or azeliragon (Arm 2).
  • Patients with psychiatric illness/social situations, including alcohol or drug abuse that in the investigator's opinion will prevent administration or completion of protocol therapy.
  • Non-English speaking, as the cognitive assessments will only be available in English

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Arm 1: Neoadjuvant RT and Temozolomide (TMZ) + Surgery or LITT + Adjuvant TMZ & Azeliragon

Radiation therapy (RT) will consist of fractionated RT to 60 Gy in 30 daily fractions administered per standard of care RTOG approach. Concurrent TMZ during RT will be self-administered by mouth (PO) as per standard of care. 1 month after completion of RT, patient will proceed with planned surgery of either resection or LITT. Patients will then receive adjuvant TMZ and azeliragon for up to 6 months. Patient should start with the loading dose 30 mg BID for 6 days before the start of adjuvant TMZ. After 6 days, azeliragon 20 mg once daily should be continued in combination with TMZ.

Provided by Cantex Pharmaceuticals

Standard of care.

Andre navne:
  • TMZ

Standard of care.

Standard of care surgical resection or laser interstitial thermal therapy (LITT).

Eksperimentel: Arm 2: Neoadjuvant RT, Temozolomide (TMZ) & Azeliragon + Surgery or LITT + Adjuvant TMZ & Azeliragon

RT will consist of fractionated RT to 60 Gy in 30 daily fractions administered per standard of care RTOG approach. Concurrent TMZ during RT will be self-administered by mouth (PO) as per standard of care. Patients will receive azeliragon as well. Azeliragon is self-administered PO. Azeliragon dosing will consist of 6 days of a loading dose of 30 mg twice per day starting on day -6, followed by 20 mg daily starting on the Day 1. Concurrent RT and TMZ start on Day 1. Azeliragon should continue until the day before planned surgical procedure. 1 month after completion of RT, patient will proceed with planned surgery of either resection or LITT. Patients will then receive adjuvant TMZ and azeliragon for up to 6 months. Patient should start with the loading dose 30 mg BID for 6 days before the start of adjuvant TMZ. After 6 days, azeliragon 20 mg once daily should be continued in combination with TMZ.

Provided by Cantex Pharmaceuticals

Standard of care.

Andre navne:
  • TMZ

Standard of care.

Standard of care surgical resection or laser interstitial thermal therapy (LITT).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Procentdel af immunsuppressive myeloide celler i tumorvævet
Tidsramme: På operationstidspunktet eller LITT (estimeret til at være dag 60)
På operationstidspunktet eller LITT (estimeret til at være dag 60)
Procentdel af immunsuppressive T-celler i tumorvævet
Tidsramme: På operationstidspunktet eller LITT (estimeret til at være dag 60)
På operationstidspunktet eller LITT (estimeret til at være dag 60)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-fri overlevelse (PFS)
Tidsramme: Op til 12 måneder efter afslutningen af ​​undersøgelsesbehandlingen (estimeret til at være 21 måneder)
Op til 12 måneder efter afslutningen af ​​undersøgelsesbehandlingen (estimeret til at være 21 måneder)
Samlet overlevelse (OS)
Tidsramme: Op til 12 måneder efter afslutningen af ​​undersøgelsesbehandlingen (estimeret til at være 21 måneder)
Op til 12 måneder efter afslutningen af ​​undersøgelsesbehandlingen (estimeret til at være 21 måneder)
Antal deltagere med bivirkninger
Tidsramme: Fra dag 1 (arm 1) eller dag -6 (arm 2) til 30 dage efter sidste dosis af Azeliragon (estimeret til at være 10 måneder)
Fra dag 1 (arm 1) eller dag -6 (arm 2) til 30 dage efter sidste dosis af Azeliragon (estimeret til at være 10 måneder)
Number of participants with intolerable toxicities
Tidsramme: From first dose of azeliragon until 30 days after the last dose (estimated to be 6-9 months)

The protocol lists the specific toxicities that are considered intolerable.

From first dose of azeliragon until 30 days after the last dose (estimated to be 6-9 months)
Feasibility of the regimen as measured by the number of participants who proceed with post-chemoradiotherapy surgery or LITT
Tidsramme: Through surgery or LITT (estimated to be 60 days)

Feasibility is defined as at least 50% of patients in each arm who are able to proceed with post-chemoradiotherapy surgery or LITT.

Through surgery or LITT (estimated to be 60 days)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Jiayi Huang, M.D., Washington University School of Medicine

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. november 2025

Primær færdiggørelse (Anslået)

28. februar 2029

Studieafslutning (Anslået)

31. august 2030

Datoer for studieregistrering

Først indsendt

12. februar 2025

Først indsendt, der opfyldte QC-kriterier

12. februar 2025

Først opslået (Faktiske)

18. februar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner